SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), and its partner Amerimmune LLC, today announced top line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy. The study demonstrated that emricasan was safe and well tolerated during the 14 days of dosing and at the day 45 follow-up, as compared to placebo with no reports of serious adverse events. Patients who completed treatment with emricasan had a complete resolution of the symptoms most commonly associated in mild COVID-19, such as cough, headache and fatigue at day 7 and continued through day 45. Patients in the placebo arm who completed the study did not experience COVID-19 symptom resolution at any time point out to day 45.
A phase 2b trial of Conatus Pharmaceuticals’ emricasan in nonalcoholic steatohepatitis (NASH) has missed its primary endpoint. The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.
The NASH party is over at Novartis-backed Conatus. And this time they’re turning off the lights.
Novartis ( NVS ) announced the signing of exclusive option, collaboration and license agreement with Conatus Pharmaceuticals Inc., to develop new oral treatments for chronic liver diseases. This agreement will enable Novartis and Conatus to jointly develop emricasan.
Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial.